GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

Mohammad Hossein Noyan-Ashraf,1 M. Abdul Momen,1 Kiwon Ban,1,6 Al-Muktafi Sadi,1 Yu-Qing Zhou,2 Ali M. Riazi,2 Laurie L. Baggio,3 R. Mark Henkelman,2 Mansoor Husain,1,4,5,6 and Daniel J. Drucker3,5

OBJECTIVE—Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before ischemic myocardial injury remain unclear.

RESEARCH DESIGN AND METHODS—We assessed the pathophysiology and outcome of coronary artery occlusion in normal and diabetic mice pretreated with the GLP-1R agonist liraglutide.

RESULTS—Male C57BL/6 mice were treated twice daily for 7 days with liraglutide or saline followed by induction of MI. Survival was significantly higher in liraglutide-treated mice. Liraglutide reduced cardiac rupture (12 of 60 versus 46 of 60; \( P = 0.0001 \)) and infarct size (21 ± 2% versus 29 ± 3%, \( P = 0.02 \)) and improved cardiac output (12.4 ± 0.6 versus 9.7 ± 0.6 ml/min; \( P = 0.002 \)). Liraglutide also modulated the expression and activity of cardioprotective genes in the mouse heart, including Akt, GSK3β, PPARγ-δ, Nrf-2, and HO-1. The effects of liraglutide on survival were independent of weight loss. Moreover, liraglutide conferred cardioprotection and survival advantages over metformin, despite equivalent glycemic control, in diabetic mice with experimental MI. The cardioprotective effects of liraglutide remained detectable 4 days after cessation of therapy and may be partly direct, because liraglutide increased cyclic AMP formation and reduced the extent of caspase-3 activation in cardiomyocytes in a GLP-1R–dependent manner in vitro.

CONCLUSIONS—These findings demonstrate that GLP-1R activation engages prosurvival pathways in the normal and diabetic mouse heart, leading to improved outcomes and enhanced survival after MI in vivo. Diabetes 58:975–983, 2009

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
LIRAGLUTIDE ACTIVATES CYTOPROTECTIVE PATHWAYS

RESEARCH DESIGN AND METHODS

Animals. Protocols were approved by the Animal Care Committee of the Toronto General Hospital in accordance with guidelines of the Canadian Council for Animal Care. Male 10- to 12-week-old C57BL/6 mice were obtained from Charles River (Montreal, PQ, Canada) and housed for at least 2 weeks before experimentation.

Drug treatments. The volume of individual i.p. injections was 100 μl. The experimental protocols are summarized in supplemental Fig. 1 (available in an online appendix at http://diabetes.diabetesjournals.org/cgi/content/full/db08-1193). One group of animals (n = 75) was injected with the GLP-1R agonist liraglutide (Novo Nordisk, Novo Alle, Bagsvaerd, Denmark) at a previously used dose of 200 μg/kg i.p. twice daily (18) for 7 days before permanent surgical ligation of the left anterior descending (LAD) artery as previously detailed (20). A parallel group of control animals (n = 75) was injected with an equivalent volume of the vehicle, PBS. After this treatment period, some animals (n = 10 per group) were killed just before planned LAD ligation with sham surgery without LAD occlusion. Because a regimen of liraglutide 200 μg/kg i.p. twice daily (LIR 200) induced weight loss in mice, we also studied the effects of LAD ligation in separate groups of mice after administration of a lower dose of liraglutide (75 μg/kg i.p. twice daily: LIR 75) that did not produce significant weight loss or pair-feeding to induce weight loss in control animals comparable to that seen in mice treated with LIR 200. Separate groups of mice received PBS or liraglutide (n = 10 each) for 7 days and were subjected to sham surgery without LAD occlusion. Animals with liraglutide were killed on day 4 post-myocardial infarction (MI) for biochemical and histological analyses. LV tissues from infarct and peri-infarct zones and remote (noninfarcted) area were obtained through a tail nick using a handheld glucometer and One-Touch Blood glucose.

Ultrasound biomicroscopy. Image acquisition and data analysis were carried out as described (28,29). Three groups of nondiabetic mice, including 8 control mice not subjected to LAD occlusion, and 15 liraglutide-treated and 15 saline-treated mice were studied on day 28 post-MI using high-frequency ultrasound imaging. Identical procedures were used to image diabetic mice (n = 5/group; LAD-ligated, n = 10–11/group).

Ischemia-reperfusion. Isolated hearts were prepared as described (27). Ischemic hearts underwent a 20-min equilibration phase followed by a 40-min perfusion phase during which LV developed pressure (LVPD) was continuously recorded. Then, 30 min of sustained global ischemia was generated by clamping inflow to the heart followed by reperfusion for 40 min. In some experiments, liraglutide was added to the buffer during the final 20 min of the perfusion phase (i.e., preischemia); in others, it was added to the buffer only during reperfusion (i.e., postischemia). Recovery of LVPD was measured at the end of reperfusion. These experiments were also performed using hearts isolated from mice after 1 day (acute) or 7 days (chronic) of twice-daily liraglutide (200 μg/kg i.p.).

Western blot. Extracts from cells, whole hearts, and infarct regions were prepared as described (26). Rabbit polyclonal primary antibodies against GLP-1R (LS-A1205; MBL International), Nrf2 (C29; Santa Cruz Biotechnology), heme-oxygenase-1 (HO-1; Stressgen), peroxisome proliferator-activated receptor-γ (PPARγ)-β/δ (H-74; Santa Cruz), and monoclonal antibodies against Akt, phospho-Akt (Ser473), glycogen synthase kinase (GSK)-3β, phospho-GSK-3β (Ser9), and cleaved-caspase 3 (all from Cell Signaling) as well as goat polyclonal anti-atrial natriuretic peptide (ANP) antibodies (Santa Cruz) were used per manufacturers’ instructions. Mouse monoclonal anti-β-actin (Sigma) and anti–transcription factor II D (TFIID) antibodies were used as a loading control and RT efficiency control.

Ischemia-reperfusion. Infarct size was determined by the use of 5-bromo-2′-deoxyuridine (BrdU) and was expressed as a percentage of the area at risk. To determine infarct size, animals were killed after the reperfusion period. Hearts were excised and fixed in 10% formaldehyde solution for 24 h, followed by 10% or 1,000 nmol/l doses of liraglutide with or without 10 μmol/l Ex9–39 followed by coinoculation with liraglutide and TNF-α (100 ng/ml; Sigma) for another 24 h to induce apoptosis (24). As a positive control for the induction of apoptosis, another group of cardiomyocytes was exposed to 0.5 μmol/l H2O2 as described (25). All experiments were performed in triplicate. Western blot analysis using whole cell extracts was used to quantify levels of cleaved caspase 3.

Cell culture, CAMP assay, and tumor necrosis factor-α–induced apoptosis. Cardiomyocytes from newborn mice were prepared using a modified protocol (23). For CAMP assay, neonatal mouse cardiac myocytes were preincubated with IBMX (250 μmol/l, Sigma) for 30 min to inhibit cAMP degradation followed by subsequent treatment periods of 20 min for liraglutide (100 nmol/l), 30 min for the GLP-1R antagonist exendin (Ex9–39) (1 μmol/l), and 15 min for forskolin (100 nmol/l). For the liraglutide + Ex9–39 treatment, cells were exposed to Ex9–39 for 30 min before coinoculation with fresh Ex9–39 and liraglutide for an additional 20 min. All experiments were performed in quadruplicate. In this group, samples were collected and analyzed using a Tecan Microplate Reader (Mannedorf, Switzerland, Life Sciences, U.K.).

Zymography. Matrix metalloproteinase-9 (MMP-9) was assessed in the infarct zone 4 days post-MI as described (22).

Ischemia-reperfusion. Isolated hearts were prepared as described (27). Ischemic hearts underwent a 20-min equilibration phase followed by a 40-min perfusion phase during which LV developed pressure (LVPD) was continuously recorded. Then, 30 min of sustained global ischemia was generated by clamping inflow to the heart followed by reperfusion for 40 min. In some experiments, liraglutide was added to the buffer during the final 20 min of the perfusion phase (i.e., preischemia); in others, it was added to the buffer only during reperfusion (i.e., postischemia). Recovery of LVPD was measured at the end of reperfusion. These experiments were also performed using hearts isolated from mice after 1 day (acute) or 7 days (chronic) of twice-daily liraglutide (200 μg/kg i.p.).
used to evaluate the difference among groups. If the ANOVA was significant, the Student-Newman-Keuls (SNK) post hoc test was used for pairwise multiple comparisons. Significance was defined as \( P < 0.05 \).

**RESULTS**

**Liraglutide increased survival in mice post-MI.** Immediate perioperative mortality (within 24 h of LAD ligation) was 8.3% in PBS- \((n = 85)\) and 5% in LIR 200–treated \((n = 60)\) mice \((P = 0.43)\) with no deaths in the sham-operated animals \((n = 20)\). By day 28 post-MI, LIR 200–treated mice exhibited reduced mortality compared with PBS-treated controls \((12 \text{ of } 60 \text{ versus } 46 \text{ of } 60; P = 0.0001)\) (Fig. 1A). Because mice treated with LIR 200 also exhibited weight loss compared with PBS-treated controls \((-1.65 \pm 0.05 \text{ versus } +0.72 \pm 0.02 \text{ g}; P = 0.0001)\), we carried out additional experiments to determine whether the effects of LIR on survival post-MI were dependent on weight loss. A separate group of mice was pair-fed to achieve weight loss comparable to that of animals receiving LIR 200 for 7 days;

**FIG. 1.** Liraglutide pretreatment improves outcomes after MI in mice. Kaplan-Meier survival curves show survival after MI in nondiabetic mice \((A)\): sham \((n = 20)\), liraglutide-MI \((75 \text{ µg/kg, } n = 35 \text{ or } 200 \text{ µg/kg, } n = 60)\), PBS-MI \((n = 60)\), and pair-fed mice \((n = 25)\), \(P = 0.0001\) for LIR 75 and 200 versus PBS; and diabetic mice \((B)\): sham \((n = 15, 5\text{/treatment group})\), PBS-MI \((n = 18)\), metformin-MI \((n = 18)\), liraglutide-MI \((75 \text{ µg/kg, } n = 18)\), \(P = 0.04\) for LIR 75 versus PBS. \(C\): Frequency and timing of cardiac rupture in nondiabetic mice is shown as a percentage of total group. One-week pretreatment with liraglutide \((200 \text{ or } 75 \text{ µg/kg i.p., twice daily})\) had no significant effects on random blood glucose levels in adult nondiabetic mice \((\text{PBS: } 7.6 \pm 4.0 \text{ versus LIR 200: } 6.3 \pm 0.6 \text{ versus LIR 75: } 6.1 \pm 0.4 \text{ mmol/l; } P = 0.72)\). Blood glucose levels in diabetic mice are shown in supplemental Table 1 (available in the online appendix).
Liraglutide reduced infarct expansion post-MI. Cardiac rupture is known to occur more frequently with larger infarcts (30) and is believed to manifest an imbalance between inflammatory and fibrotic responses as well hemodynamic forces acting on the infarct (31,32). To explore these possibilities in more detail, we first analyzed H-E-defined infarct size at day 28 post-MI in nondiabetic mice. Liraglutide (LIR 200) significantly reduced infarct size compared with PBS-treated mice (20.9 ± 1.7 versus 28.8 ± 3.3; percent total LV circumference, P = 0.02) (Fig. 2). Furthermore, cardiac hypertrophy, as manifested by heart weight/body weight (HW/BW) ratio, was significantly reduced in LIR 200–treated mice (Fig. 2). To determine if these results partly reflected survivor bias, we also examined TTC-defined infarct size at day 2 post-MI. This analysis revealed no significant difference in infarct size between LIR 200– (n = 14) and PBS-treated (n = 15) groups (40.2 ± 4.2 versus 39.3 ± 3.8; P = 0.86). Despite significantly higher survival in liraglutide-treated diabetic mice (Fig. 1B), no differences were observed in either infarct size or HW/BW ratios in diabetic animals at day 28 post-MI (data not shown).

**Liraglutide activates cardioprotective signaling pathways in the heart.** To determine the mechanisms underlying liraglutide-induced improvements in survival and infarct remodeling post-MI, we studied the expression of selected genes and proteins known to modulate cardiomyocyte survival. LIR 200 administered twice daily for 7 days to normal healthy mice (without MI) increased phosphorylation of the prosurvival kinase Akt (pAkt/Akt: 2.10 ± 0.04 versus 0.85; P < 0.001). Data shown are means ± SE. (A high-quality digital representation of this figure is available in the online issue.)

![Graph showing effects of liraglutide pretreatment on infarct size and heart weight. A: Representative photomicrographs of H-E-stained hearts 28 days post-MI depict decreased infarct size (arrows) in liraglutide- (n = 36) versus PBS-treated mice (n = 21) as confirmed by morphometric quantification of percent total LV circumference (**P = 0.025). B: HW/BW ratio was reduced in liraglutide- versus PBS-treated mice 28 days post-MI (n = 36 and 21, respectively; *P = 0.001). Data shown are means ± SE. (A high-quality digital representation of this figure is available in the online issue.)](image)

no difference in survival was noted between mice treated with LIR 200 versus pair-fed controls (Fig. 1A). We next assessed a range of liraglutide doses on food intake and body weight and then determined the effect of pretreatment with a weight-neutral dose, LIR 75, on post-MI survival. Mice treated with LIR 75 for 7 days did not experience significant weight loss (0.30 ± 0.06 g; P = 0.85) but exhibited a marked improvement in survival after LAD ligation (Fig. 1A, P = 0.0001). Similarly, pretreatment of diabetic mice for 1 week with LIR 75 also reduced mortality after LAD occlusion (Fig. 1B, P = 0.04); in contrast, comparable treatment with metformin that produced equivalent reduction in glycemia (supplemental Table 1, available in the online appendix) did not improve survival after MI (P = 0.5, not significant). Together, these data suggest that pretreatment with liraglutide enhances survival after MI independent of effects on body weight or blood glucose.

**Liraglutide prevented cardiac rupture post-MI.** To understand the mechanisms by which LIR improves outcomes after MI in mice, we performed postmortem examinations of all animals. Excluding day 1, postmortem analysis in nondiabetic mice revealed that all spontaneous death events within 10 days post-MI were associated with evidence of cardiac rupture. Timing and incidence of cardiac rupture differed among the groups, occurring as early as day 3 post-MI and peaking in incidence at day 5 post-MI in PBS-treated mice (Fig. 1C). By contrast, mice pretreated with LIR 200, and to an even greater extent LIR 75, exhibited fewer and later cardiac rupture events post-MI (Fig. 1C).
Liraglutide-treated mice exhibit improved cardiac performance. The results of cardiac ultrasound biomicroscopy performed 4 weeks after LAD ligation or sham surgery in nondiabetic mice are shown in Table 1. After experimental MI, measures of systolic function such as cardiac output and stroke volume were significantly increased in liraglutide-treated mice. Measures of diastolic function such as mitral inflow velocities (E/A ratio) were also improved in liraglutide-treated mice and LV dilatation in the liraglutide-treated group was less severe than in PBS-treated control mice (Table 1). In contrast, although liraglutide-treated diabetic mice exhibited a significant
increase in cardiac output in the absence of experimental MI, no consistent differences in echocardiographic parameters were detected in diabetic mice treated with liraglutide versus metformin at day 28 post-MI (data not shown).

Liraglutide treatment in vivo prevented ischemia–reperfusion injury of isolated hearts ex vivo. To determine whether liraglutide exhibits rapid cardioprotective actions in the isolated mouse heart ex vivo, we examined the effects of acute liraglutide administration in the isolated perfused mouse heart. Direct infusions of liraglutide immediately before and postischemia did not improve functional recovery after ischemia-reperfusion (I/R) injury in the isolated mouse heart (Fig. 5A). In contrast, pretreatment of normal healthy mice with liraglutide (200 μg/kg b.i.d.) in vivo for 1 or 7 days before heart isolation enhanced recovery of LVDP after I/R relative to untreated controls (1 day: 41.54 ± 1.5, n = 4; 7 days: 38.31 ± 0.6 mmHg, n = 5; untreated: 28.24 ± 1.8 mmHg, n = 5; P < 0.01, Fig. 5B). These results imply that liraglutide-induced cardioprotection may require a minimum dose or pretreatment period for the activation of a cardiac gene and protein expression profile and/or may be indirect, reflecting the consequences of GLP-1R activation in noncardiac tissues.

Liraglutide induces cAMP and reduces apoptosis in neonatal mouse cardiomyocytes. We next examined whether liraglutide exerts direct actions on mouse cardiomyocytes. Liraglutide (100 nmol/l) significantly increased cAMP formation in mouse cardiomyocytes (P < 0.0001) in a GLP-1R–dependent manner, because cAMP stimulation was abolished by the GLP-1R antagonist Ex9–39 (Fig. 6A). To determine whether liraglutide directly modulates cardiomyocyte survival, we examined the effects of liraglutide in TNF-α–treated neonatal cardiomyocytes. Liraglutide dose-dependently reduced TNF-α–induced activation of caspase 3 in cardiomyocytes in vitro. Furthermore, the protective effect of liraglutide was completely abolished after coinubcation of cells with Ex9–39 (Fig. 6B).

DISCUSSION

In the present study, we demonstrate that liraglutide administration induced changes in the expression of cardioprotective proteins in the normal nonatherosclerotic murine heart characterized by phosphorylation of Akt and GSK3β and increased expression of Nrf2, PPAR-β/δ, and HO-1. These changes were associated with improved survival of mice after experimental ischemia despite cessation of liraglutide therapy. These findings, taken together with the results of echocardiography, demonstrate that a brief 7-day period of liraglutide pretreatment leads to improvements in cardiomyocyte survival and sustained improvement in cardiac function that remain detectable even 4 weeks after cessation of liraglutide and induction of experimental MI.

**TABLE 1**

Ultrasound biomicroscopy-defined cardiac dimensional, functional, and hemodynamic parameters in mice on day 28 postoperatively

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Sham</th>
<th>MI-placebo</th>
<th>MI-liraglutide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>27.9 ± 0.3</td>
<td>29.5 ± 0.4</td>
<td>29.3 ± 0.5</td>
</tr>
<tr>
<td>Aortic flow</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>393 ± 12</td>
<td>451 ± 18</td>
<td>435 ± 12</td>
</tr>
<tr>
<td>Peak velocity (cm/s)</td>
<td>86.3 ± 2.2</td>
<td>68.7 ± 2.7*</td>
<td>80.3 ± 3.2†</td>
</tr>
<tr>
<td>VTI (cm)</td>
<td>3.03 ± 0.08</td>
<td>2.09 ± 0.13*</td>
<td>2.61 ± 0.12‡</td>
</tr>
<tr>
<td>AO diameter (mm)</td>
<td>1.15 ± 0.02</td>
<td>1.15 ± 0.02</td>
<td>1.19 ± 0.01</td>
</tr>
<tr>
<td>LV SV (μl)</td>
<td>31.3 ± 0.9</td>
<td>22.1 ± 1.8†</td>
<td>28.8 ± 1.4†</td>
</tr>
<tr>
<td>CO (ml/min)</td>
<td>12.3 ± 0.5</td>
<td>9.7 ± 0.6‡</td>
<td>12.4 ± 0.6‡</td>
</tr>
<tr>
<td>Mitral flow</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>413 ± 11</td>
<td>433 ± 14</td>
<td>424 ± 9†</td>
</tr>
<tr>
<td>Peak E velocity (cm/s)</td>
<td>71.8 ± 1.9</td>
<td>59.0 ± 3.6*</td>
<td>59.9 ± 2.2*</td>
</tr>
<tr>
<td>Peak A velocity (cm/s)</td>
<td>47.0 ± 1.5</td>
<td>30.8 ± 3.5*</td>
<td>43.6 ± 2.0†</td>
</tr>
<tr>
<td>Peak E/A ratio</td>
<td>1.54 ± 0.04</td>
<td>2.54 ± 0.44*</td>
<td>1.40 ± 0.06†</td>
</tr>
<tr>
<td>LV chamber dimensions by M mode</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>417 ± 10</td>
<td>442 ± 17</td>
<td>441 ± 15</td>
</tr>
<tr>
<td>LV EDD (mm)</td>
<td>4.33 ± 0.05</td>
<td>6.12 ± 0.23*</td>
<td>5.52 ± 0.09†</td>
</tr>
<tr>
<td>LV ESD (mm)</td>
<td>3.33 ± 0.08</td>
<td>5.73 ± 0.30*</td>
<td>5.02 ± 0.14‡</td>
</tr>
<tr>
<td>LV FS (%)</td>
<td>23.0 ± 1.2</td>
<td>7.0 ± 1.5*</td>
<td>9.2 ± 1.3*</td>
</tr>
</tbody>
</table>

Data are means ± SE. In mitral inflow, the peak E velocity represents the maximal velocity of the early diastolic wave caused by active LV relaxation. The peak A velocity represents the maximal velocity caused by left atrial contraction in late diastole. *Difference (P < 0.05) with the corresponding value in the sham controls. †Difference (P < 0.05) with the corresponding value in the placebo (PBS)-treated controls. AO, aortic orifice; CO, cardiac output; FS, fractional shortening; SV, stroke volume; EDD, end-diastolic diameter; ESD, end-systolic diameter; VTI, velocity–time integral of Doppler flow waveform.
The beneficial effects of liraglutide were independent of weight loss, because a lower dose of liraglutide (75 μg/kg) that did not produce weight loss also protected the heart and increased survival to a greater extent than that observed with the higher 200 μg/kg liraglutide dose. The weight loss observed with higher pharmacological doses of GLP-1R agonists is not required for the beneficial effects of these agents on cardiovascular function (2).

Although the mechanisms underlying the reduced cardiac rupture and improved survival remain incompletely understood, notable findings from our studies include the modulation of putative mediators (Akt, GSK3β, HO-1, PPAR-β/δ, and Nrf2) known to be important for cardiomyocyte survival (34–38). We observed reduced levels of MMP-9 and cleaved caspase 3 in the infarct region of liraglutide-treated mice at day 4 post-MI. These findings are reminiscent of observations made in studies of the effects of GLP-1 on survival of β-cells and neurons, in which GLP-1R activation leads to inhibition of caspase activation and increased cytoprotection (39,40).

Functional assessment with echocardiography showed that LV systolic function remained improved even 4 weeks after the last dose of liraglutide. We observed significantly less dilatation of the left ventricle of liraglutide-treated mice. These findings are consistent with preclinical data demonstrating that GLP-1R agonists improve LV function in rodent and canine models of experimental cardiac dysfunction (8,9,11–13,41). The sustained benefits of transient liraglutide therapy that persisted for weeks after cessation of therapy is consistent with studies demonstrating that a 72-h infusion of GLP-1 in human subjects after MI produces sustained improvements in cardiovascular function that remained detectable even months after cessation of GLP-1 administration (14).

An unexpected finding was the observation that liraglutide, unlike native GLP-1 or GLP-19–36 (3), was not effective in directly improving LV pressure, or recovery of...
LV pressure after I/R injury, when administered either immediately before induction of ischemia or during the reperfusion phase to isolated hearts ex vivo. In contrast, administration of liraglutide in vivo for as little as 1 day (two injections) before ischemia was sufficient to confer a cardioprotective benefit in subsequent I/R experiments. Our findings raise the possibility that the cardioprotective actions of liraglutide are complex and may require a specific minimum dose or defined time period for induction of a protective gene/protein profile that promotes resistance to cardiomyocyte injury. Alternatively, the cardioprotective actions of liraglutide observed in vivo may be partly indirect, mediated perhaps through neural, hormonal, or metabolic factors. This latter possibility contrasts with findings demonstrating direct protection by native GLP-1 in I/R studies (9,10,42).

Recent studies have implicated a role for the metabolite GLP-19 –36 as a cardioactive peptide with inotropic effects in dogs with heart failure (41). The GLP-1 metabolite, GLP-19 –36, also exerts cardioprotective actions when administered posts ischemia (3,16), further highlighting the complexity of different GLP-1-related peptides on the ischemic heart. Liraglutide is relatively resistant to cleavage by DPP-4 and contains two amino acid modifications, a substitution and an addition, together with a fatty acid side chain. Whether liraglutide is metabolized to a peptide with GLP-19 –36-like activity remains unclear. The observation that liraglutide fails to induce the phosphorylation of Akt and GSK3β in the Glp1r/-/- heart, together with the demonstration that liraglutide increased cAMP and reduced apoptosis in cardiomyocyte cultures in a GLP-1R-dependent manner, strongly implicates the known GLP-1R as a critical mediator of liraglutide action in the murine heart.

Drugs acting on the GLP-1R axis have been approved for the treatment of diabetes and have the added benefits of reducing appetite and body weight and, in some instances, blood pressure, leading to improvement of cardiovascular risk factors (43,44). Given the experimental data presented here and elsewhere (8,9,13,16), the possibility that these agents may have beneficial effects on cardiovascular outcomes of patients with diabetes, independent of improvements in blood pressure and blood glucose, requires further study.

ACKNOWLEDGMENTS

These studies were supported in part by grants from the Heart and Stroke Foundation of Ontario (NA5926), CIHR Grant IRO 80668, and Novo Nordisk. L.L.B. has served as a panel member and/or received a speaker’s honorarium for symposia sponsored by Novo Nordisk, Merck Frosst, and GlaxoSmithKline. M.H. has served as a consultant to sanofi-aventis and Merck & Co. D.D. has served as an advisor or consultant to Amylin Pharmaceuticals, Arena, Arisaph Pharmaceuticals, ConjuChem, Eli Lilly, Emisphere Technologies, GlaxoSmithKline, Glenmark Pharmaceuticals, Hoffman LaRoche, Isis Pharmaceuticals, Mannkind, Merck Research Laboratories, Metabolex, Novartis Pharmaceuticals, Novo Nordisk, Phenomix, Takeda, and Transition Pharmaceuticals. No other potential conflicts of interest relevant to this article were reported.

Parts of this study were presented in abstract form at the 68th Scientific Sessions of the American Diabetes Association, San Francisco, California, 6–10 June 2008.

REFERENCES

10. Bose AK, Mocanu MM, Carr RD, Yellon DM: Glucagon-like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 19:9–11, 2005
Random tail blood glucose (BG) levels in mice employed for generating the high fat diet (HFD)- and streptozotocin (STZ)- model of diabetes. Data are expressed as mean ± SE. No significant differences were observed in liraglutide vs. metformin-treated groups at any time-points. Although body weight did not change in MET-treated animals (d0: 27.3±0.5 vs. d7: 27.5 ± 0.4, g P=0.72), LIR 75-treated diabetic mice experienced modest weight loss (d0: 26.7 ± 0.5 vs. d7: 24.9 ± 0.7, g, P=0.04).
### Experimental design

#### START
- D1

#### END
- D7
- D8
- D12
- D36

#### 7d treatment period
- Group A: 200 ug/Kg liraglutide bid
- Group B: 75 ug/Kg liraglutide bid
- Group C: PBS (Placebo)
- Group D: pair-feeding

#### 4dpMI: Sacrifice:
- Dissection of the infarct zone
- HW/BW
- Zymography
- Western Blot

#### 28dpMI:
- UBM
- Sacrifice
- HW / BW
- Histology
- Morphometry

- Western Blot
- PCR
- Microarray